CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Santa Cruz De Teneriffe, Spain

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

    Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With HER2 Negative Locally Advanced, Recurrent or Metastatic Gastric, Oesophageal or Oesogastric Junction Adenocarcinoma

    Phase

    2

    Span

    189 weeks

    Sponsor

    UNICANCER

    Coudekerque-Branche

    Recruiting

  • Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer

    Phase

    N/A

    Span

    262 weeks

    Sponsor

    Centre Francois Baclesse

    Coudekerque-Branche

    Recruiting

  • Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

    Phase

    2

    Span

    182 weeks

    Sponsor

    Federation Francophone de Cancerologie Digestive

    Coudekerque-Branche

    Recruiting

  • Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach

    Phase

    N/A

    Span

    363 weeks

    Sponsor

    Gustave Roussy, Cancer Campus, Grand Paris

    Coudekerque-Branche

    Recruiting

  • Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

    Phase

    N/A

    Span

    162 weeks

    Sponsor

    UNICANCER

    Dunkerque

    Recruiting

  • OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

    Phase

    N/A

    Span

    70 weeks

    Sponsor

    French Innovative Leukemia Organisation

    Dunkerque

    Recruiting

  • Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

    The ASSURE-3 study is a national, multicentric, non-interventional, prospective study in real-life conditions with primary data collection in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more Tyrosine Kinase Inhibitors (TKIs). It will be conducted in France with hematologists, onco-hematologists, physicians with documented involvement in managing Ph+ CML-CP patients in routine practice, practicing in public or private health care institutions. Each patient will be followed during 15 months at M0, M1 and then every 3 months (rhythm of visits according to the routine clinical care), or until premature discontinuation of asciminib treatment. Historical data will be abstracted retrospectively by the participating physicians from patient files, to collect information using an electronic case report form (eCRF). Primary data will be collected during inclusion and follow-up visits

    Phase

    N/A

    Span

    145 weeks

    Sponsor

    Novartis Pharmaceuticals

    Dunkerque

    Recruiting

  • Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

    Phase

    N/A

    Span

    159 weeks

    Sponsor

    Intergroupe Francophone du Myelome

    Dunkerque

    Recruiting

  • 6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis

    Phase

    N/A

    Span

    110 weeks

    Sponsor

    Aptissen SA

    Dunkerque

    Recruiting

  • Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

    Included patients will be followed until the end of study, death or lost to follow-up even if ribociclib and ET are discontinued. The end of the study is defined as 3 years after the first visit of the last patient included (Last Patient First Visit [LPFV]). The total duration of the study will be 4 years and half (18 months of inclusion + 3 years of follow-up). Thus, a patient included at the beginning of the inclusion period will be followed for 4 years and half and a patient included at the end of the inclusion period will be followed for at least 3 years.

    Phase

    N/A

    Span

    290 weeks

    Sponsor

    Novartis Pharmaceuticals

    Dunkerque

    Recruiting

1-10 of 31
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information